MURFITTS INDUSTRIES LIMITED

Company number 04012599 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: MURFITTS INDUSTRIES LIMITED

1. Financial Health Score: A-

Explanation: The patient is in excellent physical condition, demonstrating robust growth, strong profitability, and a very healthy balance sheet. The acquisition by European Tyre Enterprise Limited (ETEL) acts as a powerful "immune booster," providing significant corporate backing. The only minor concerns are a slightly elevated "dividend drain" which reduces retained cash, and external macroeconomic "pathogens" (energy costs, inflation) that require ongoing monitoring.


2. Key Vital Signs

  • Pulse Rate (Revenue Growth): Strong and Elevated. Turnover increased by 19.7% from £15.28m (2020) to £18.28m (2021). This indicates a vigorous, expanding business rather than a stagnant one, showing excellent post-pandemic recovery.
  • Muscle Mass (Profitability): Very Strong. Gross profit grew from £7.4m to £9.0m, and Profit Before Tax (PBT) jumped from £1.7m to £2.5m (a 47% increase). The PBT margin sits at a healthy 13.7%, showing the company isn't just growing revenue, but converting it efficiently into bottom-line strength.
  • Blood Pressure (Leverage/Liabilities): Normal and Stable. Total liabilities increased from £4.65m to £6.88m, but total assets grew to £21.76m. The liability-to-asset ratio is roughly 31.6%. This is the financial equivalent of excellent blood pressure—the company is not over-leveraged and is in no danger of a debt-induced "cardiac event."
  • Immune System (Cash Reserves): Strengthening. Cash on hand more than doubled from £511k (2020) to £1.25m (2021). A healthy cash reserve ensures the business can fight off short-term shocks without resorting to expensive external financing.
  • Bone Density (Net Assets/Equity): Solid. Net assets stand at £11.73m, providing a very thick cushion against potential future losses.

3. Diagnosis

Overall Condition: Robust and Thriving

The financial data reveals a business with the financial constitution of a seasoned athlete. The core "organs" of the business are functioning exceptionally well. The 19.7% increase in turnover is a clear symptom of strong market demand and operational capacity, likely aided by the strategic acquisition of CE Holdings Limited, which expanded their processing capabilities.

However, a thorough examination reveals two notable symptoms to monitor:

  1. The Dividend Drain: The company paid out £2.15m in ordinary dividends. While paying dividends is generally a sign of a healthy, mature business (returning nutrients to the parent company), this payout represents approximately 86% of the pre-tax profit. Siphoning off this much capital leaves less retained earnings to organically fund future R&D and capital expenditures, making the company more reliant on external backing for major investments.
  2. External Pathogens (Macro Risks): The Directors' report explicitly identifies the war in Ukraine as a source of "significant challenges," specifically referencing increased energy costs and pressure on tyre income due to shifts in the Indian market. Because tyre recycling is highly energy-intensive, spiking energy costs act as an autoimmune flare-up, attacking the company's gross margins if they cannot pass those costs onto customers.

The recent acquisition by ETEL is a major structural change. It effectively acts as a "blood transfusion" from a larger parent organization (which owns Kwik-Fit and Stapleton's), guaranteeing a steady pipeline of end-of-life tyres and providing deep pockets to fund the ongoing pyrolysis R&D.


4. Recommendations

To maintain this excellent financial health and guard against future illness, the following regimen is prescribed:

  • Hedge Against Energy Fevers: Given the energy-intensive nature of rubber manufacturing and recycling, the company must aggressively manage its energy contracts. Implementing long-term fixed-price energy agreements and investing in energy-efficiency retrofits for plant machinery will protect margins from future price spikes.
  • Retain Cash for R&D Immunity: While the ETEL acquisition provides backing, the company should carefully balance dividend payouts to the parent company with the need to reinvest in the business. The pyrolysis plant represents a major future revenue stream; starving this project of capital now could compromise the company's long-term health.
  • Monitor Working Capital Circulation: As the business scales, ensuring that debtors pay on time and that inventory doesn't become sluggish will be critical. A healthy cash flow requires excellent "circulation"—money must keep moving through the system efficiently.

Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 21 August 2026